Spero Therapeutics, Inc. Diluted Shares Outstanding (Weighted Average)
Spero Therapeutics, Inc. (SPRO) reported Diluted Shares Outstanding (Weighted Average) of 57.97 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-12
- Spero Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 57.97M shares, a 3.47% increase year-over-year.
- Spero Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 57.28M shares, a 3.44% increase year-over-year.
- Spero Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 68.56M shares, a 25.70% increase year-over-year.
- Spero Therapeutics, Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 56.28M shares, a 3.98% increase year-over-year.
- Spero Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2025 was 59.04M shares, a 9.26% increase from fiscal 2024.
- Spero Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2024 was 54.04M shares, a 1.98% increase from fiscal 2023.
- Spero Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2023 was 52.99M shares, a 40.98% increase from fiscal 2022.
- Spero Therapeutics, Inc. weighted average number of shares outstanding, diluted for fiscal 2022 was 37.59M shares, a 21.65% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 57.97M shares 10-Q · filed 2026-08-12 | 57.63M shares 10-Q · filed 2026-08-12 | 61.27M shares derived: average of 3 quarters · filed 2026-08-12 | 60.02M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | 57.28M shares 10-Q · filed 2026-05-13 | 62.92M shares derived: average of 2 quarters · filed 2026-05-13 | 60.71M shares derived: average of 3 quarters · filed 2026-05-13 | 59.54M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | 68.56M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 62.42M shares derived: average of 2 quarters · filed 2026-03-26 | 60.29M shares derived: average of 3 quarters · filed 2026-08-12 | 59.04M shares 10-K · filed 2026-03-26 |
| 2025-09-30 | 56.28M shares 10-Q · filed 2025-11-13 | 56.15M shares derived: average of 2 quarters · filed 2026-08-12 | 55.87M shares 10-Q · filed 2025-11-13 | 55.56M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | 56.03M shares 10-Q · filed 2026-08-12 | 55.70M shares 10-Q · filed 2026-08-12 | 55.32M shares derived: average of 3 quarters · filed 2026-08-12 | 55.02M shares derived: average of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | 55.38M shares 10-Q · filed 2026-05-13 | 54.96M shares derived: average of 2 quarters · filed 2026-05-13 | 54.68M shares derived: average of 3 quarters · filed 2026-05-13 | 54.50M shares derived: average of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | 54.54M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | 54.33M shares derived: average of 2 quarters · filed 2026-03-26 | 54.21M shares derived: average of 3 quarters · filed 2026-03-26 | 54.04M shares 10-K · filed 2026-03-26 |
| 2024-09-30 | 54.12M shares 10-Q · filed 2025-11-13 | 54.04M shares derived: average of 2 quarters · filed 2025-11-13 | 53.87M shares 10-Q · filed 2025-11-13 | 53.94M shares derived: average of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | 53.96M shares 10-Q · filed 2025-08-12 | 53.74M shares 10-Q · filed 2025-08-12 | 53.88M shares derived: average of 3 quarters · filed 2025-08-12 | 53.58M shares derived: average of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | 53.52M shares 10-Q · filed 2025-05-13 | 53.83M shares derived: average of 2 quarters · filed 2025-05-13 | 53.46M shares derived: average of 3 quarters · filed 2025-05-13 | 53.24M shares derived: average of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | 54.14M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 53.43M shares derived: average of 2 quarters · filed 2025-03-27 | 53.14M shares derived: average of 3 quarters · filed 2025-03-27 | 52.99M shares 10-K · filed 2025-03-27 |
| 2023-09-30 | 52.71M shares 10-Q · filed 2024-11-14 | 52.64M shares derived: average of 2 quarters · filed 2024-11-14 | 52.60M shares 10-Q · filed 2024-11-14 | 51.66M shares derived: average of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | 52.57M shares 10-Q · filed 2024-08-05 | 52.55M shares 10-Q · filed 2024-08-05 | 51.31M shares derived: average of 3 quarters · filed 2024-08-05 | 47.45M shares derived: average of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | 52.53M shares 10-Q · filed 2024-05-15 | 50.68M shares derived: average of 2 quarters · filed 2024-05-15 | 45.75M shares derived: average of 3 quarters · filed 2024-05-15 | 42.56M shares derived: average of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | 48.84M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | 42.36M shares derived: average of 2 quarters · filed 2024-03-13 | 39.23M shares derived: average of 3 quarters · filed 2024-03-13 | 37.59M shares 10-K · filed 2024-03-13 |
| 2022-09-30 | 35.88M shares 10-Q · filed 2023-11-13 | 34.43M shares derived: average of 2 quarters · filed 2023-11-13 | 33.83M shares 10-Q · filed 2023-11-13 | 33.45M shares derived: average of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | 32.98M shares 10-Q · filed 2023-08-10 | 32.79M shares 10-Q · filed 2023-08-10 | 32.64M shares derived: average of 3 quarters · filed 2023-08-10 | 32.51M shares derived: average of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | 32.61M shares 10-Q · filed 2023-05-11 | 32.47M shares derived: average of 2 quarters · filed 2023-05-11 | 32.36M shares derived: average of 3 quarters · filed 2023-05-11 | 31.69M shares derived: average of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | 32.33M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | 32.23M shares derived: average of 2 quarters · filed 2023-03-30 | 31.38M shares derived: average of 3 quarters · filed 2023-03-30 | 30.90M shares 10-K · filed 2023-03-30 |
| 2021-09-30 | 32.13M shares 10-Q · filed 2022-11-14 | 30.90M shares derived: average of 2 quarters · filed 2022-11-14 | 30.42M shares 10-Q · filed 2022-11-14 | |
| 2021-06-30 | 29.68M shares 10-Q · filed 2022-08-10 | 29.55M shares 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |